UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

The Journal of infectious diseases, 2017-06, Vol.215 (11), p.1725-1733

2017

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Assessment of Oral Valganciclovir in the Treatment of Symptomatic Congenital Cytomegalovirus Disease

The Journal of infectious diseases, 2008-03, Vol.197 (6), p.836-845

2008

Volltextzugriff (PDF)

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Breast cancer research : BCR, 2021-03, Vol.23 (1), p.30-12, Article 30

2021

Volltextzugriff (PDF)

Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis

American journal of obstetrics and gynecology, 2015-06, Vol.212 (6), p.812.e1-812.e6

2015

Volltextzugriff (PDF)

Pharmacokinetic Enhancers in HIV Therapeutics

Clinical pharmacokinetics, 2014-10, Vol.53 (10), p.865-872

2014

Volltextzugriff (PDF)

Efficacy of a nucleoside-sparing regimen of darunavir/ ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

AIDS (London), 2011-11, Vol.25 (17), p.2113-2122

2011

Volltextzugriff (PDF)

Current Status of the Pharmacokinetics and Pharmacodynamics of HIV-1 Entry Inhibitors and HIV Therapy

Current drug metabolism, 2017-10, Vol.18 (8), p.769

2017

Volltextzugriff (PDF)

A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model

PLoS pathogens, 2012-06, Vol.8 (6), p.e1002774-e1002774

2012

Volltextzugriff (PDF)

Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

The Journal of infectious diseases, 2010-09, Vol.202 (5), p.717-722

2010

Volltextzugriff (PDF)

Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1–Infected Subjects

The Journal of infectious diseases, 2008-03, Vol.197 (6), p.867-870

2008

Volltextzugriff (PDF)

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

Annals of internal medicine, 2005-11, Vol.143 (10), p.714

2005

Volltextzugriff (PDF)

Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior

Frontiers in pharmacology, 2022-05, Vol.13, p.863762

2022

Volltextzugriff (PDF)

Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study

BMC cancer, 2022-01, Vol.22 (1), p.60-60, Article 60

2022

Volltextzugriff (PDF)

Oseltamivir Dosing for Influenza Infection in Premature Neonates

The Journal of infectious diseases, 2010-08, Vol.202 (4), p.563-566

2010

Volltextzugriff (PDF)

Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1

Infectious diseases and therapy, 2024-08, Vol.13 (8), p.1877-1891

2024

Volltextzugriff (PDF)

Raltegravir pharmacokinetics in neonates following maternal dosing

Journal of acquired immune deficiency syndromes (1999), 2014-11, Vol.67 (3), p.310-315

2014

Volltextzugriff (PDF)

Novel Method To Assess Antiretroviral Target Trough Concentrations Using In Vitro Susceptibility Data

Antimicrobial Agents and Chemotherapy, 2012-11, Vol.56 (11), p.5938-5945

2012

Volltextzugriff (PDF)

Associations between CYP2B6 Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans

The Journal of infectious diseases, 2009-03, Vol.199 (6), p.872-880

2009

Volltextzugriff (PDF)

Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer

Cells (Basel, Switzerland), 2020-08, Vol.9 (9), p.1976

2020

Volltextzugriff (PDF)

Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway

Oncotarget, 2017-03, Vol.8 (10), p.17216-17228

2017

Volltextzugriff (PDF)

Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study

Clinical infectious diseases, 2006-02, Vol.42 (3), p.401-407

2006

Volltextzugriff (PDF)

Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens

Clinical infectious diseases, 2021-05, Vol.72 (10), p.1820-1822

2021

Volltextzugriff (PDF)

Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

CPT: pharmacometrics and systems pharmacology, 2019-09, Vol.8 (9), p.643-653

2019

Volltextzugriff (PDF)

Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study

PloS one, 2013-12, Vol.8 (12), p.e82672

2013

Volltextzugriff (PDF)

Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee

Retrovirology, 2017-06, Vol.14 (1), p.35-9, Article 35

2017

Volltextzugriff (PDF)

1 – 25 von 281

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(251)
Mit Volltextzugriff
(213)

Publikationsform

Artikel
(276)
Berichte
(4)
Bücher
(1)

Sprache

Englisch
(281)
Japanisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

Pharmacokinetic and Pharmacodynamic Assessment of Oral Valganciclovir in the Treatment of Symptomatic Congenital Cytomegalovirus Disease

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis

Pharmacokinetic Enhancers in HIV Therapeutics

Efficacy of a nucleoside-sparing regimen of darunavir/ ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

Current Status of the Pharmacokinetics and Pharmacodynamics of HIV-1 Entry Inhibitors and HIV Therapy

A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model

Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1–Infected Subjects

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior

Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study

Oseltamivir Dosing for Influenza Infection in Premature Neonates

Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1

Raltegravir pharmacokinetics in neonates following maternal dosing

Novel Method To Assess Antiretroviral Target Trough Concentrations Using In Vitro Susceptibility Data

Associations between CYP2B6 Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans

Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer

Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway

Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study

Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens

Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study

Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee

Suchergebnisse filtern